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Abstract
HIV uncoating is defined as the loss of viral capsid that occurs within the cytoplasm of infected cells before entry
of the viral genome into the nucleus. It is an obligatory step of HIV-1 early infection and accompanies the
transition between reverse transcription complexes (RTCs), in which reverse transcription occurs, and pre-integration
complexes (PICs), which are competent to integrate into the host genome. The study of the nature and timing of
HIV-1 uncoating has been paved with difficulties, particularly as a result of the vulnerability of the capsid assembly to
experimental manipulation. Nevertheless, recent studies of capsid structure, retroviral restriction and mechanisms of
nuclear import, as well as the recent expansion of technical advances in genome-wide studies and cell imagery
approaches, have substantially changed our understanding of HIV uncoating. Although early work suggested that
uncoating occurs immediately following viral entry in the cell, thus attributing a trivial role for the capsid in infected
cells, recent data suggest that uncoating occurs several hours later and that capsid has an all-important role in the
cell that it infects: for transport towards the nucleus, reverse transcription and nuclear import. Knowing that
uncoating occurs at a later stage suggests that the viral capsid interacts extensively with the cytoskeleton and other
cytoplasmic components during its transport to the nucleus, which leads to a considerable reassessment of our
efforts to identify potential therapeutic targets for HIV therapy. This review discusses our current understanding of
HIV uncoating, the functional interplay between infectivity and timely uncoating, as well as exposing the appropriate
methods to study uncoating and addressing the many questions that remain unanswered.
Structure of mature HIV-1 capsid and its
importance at early stages of infection
The mature HIV-1 capsid, also called HIV-1 core, is a
highly organised macromolecular assembly, formed
within newly released virions upon proteolytic cleavage
of the precursor p55Gag polyprotein by the viral pro-
tease which generates the cleavage product CA (also
called capsid or p24). Rather confusingly, the term cap-
sid refers both to the conical multimeric structure and
to the CA monomers that constitute the cone. There-
fore, to avoid all confusion, the terms “capsid” and
“core” are preferred for reference to the conical struc-
ture and monomers are referred to as “CA”. Negative
staining and cryo-electron microscopy of authentic
mature particles or isolated mature HIV-1 cores reveal
that capsids have an intriguing conical shape, with a
relatively consistent length of 100-120 nm [1-4] (Figure 1).
The diameter of the wide end of the capsid cone (50-60
nm) and the angle at the tip of the cone (18-24°) may vary
and lead to capsids with apparent heterogeneity of shape
(bullet shape, cylindrical forms).
The intrinsic properties of the HIV-1 capsid, such as
its poor stability or asymmetry, have made it particularly
difficult to explore the detailed structure of mature
cores isolated from disrupted virions. However, recom-
binant CA can spontaneously assemble in vitro into
cones and structures analogous to authentic HIV-1 cap-
sids [5] and much of the valuable information we have
on the shape and underlying molecular structures of the
capsid derive from core-like structures obtained from in
vitro CA assembly reactions. These have shown that
despite its macromolecular asymmetry, the HIV-1 capsid
is assembled with a high degree of organisation as a full-
erene cone, a structure with hexagonal lattice symmetry
that is capped at both ends [5,6]. The HIV-1 capsid is
made up of ca. 1,500 CA monomers, which assemble
into 250 hexameric rings through NTD-NTD (N-term-
inal domain) interactions, which are themselves linked
into a hexagonal lattice through CTD-CTD (C-terminal
domain) interactions [7,8]. The hexagonal lattice is
curved into a cone through subunit mobility [8] and isCorrespondence: nathalie.arhel@pasteur.fr
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capped by exactly 12 pentameric rings, 7 at the wide
end and 5 at the narrow end of the cone [5].
The capsid contains the viral genome (two single
stranded RNA molecules), some viral proteins (CA,
nucleocapsid (NC), reverse transcriptase (RT), integrase
(IN), Vpr) and numerous cellular proteins, such as
Cyclophilin A and APOBEC3G [9]. Its main function is
to organise and contain the viral genome for optimal
delivery in target cells and efficient reverse transcription,
which together contribute to effective replication in the
new host cell. The capsid cone is absolutely essential for
infection since mutations of protease cleavage sites in
Gag, or inhibitors of Gag processing, produce immature
virions and abolish HIV-1 infectivity [10-13]. Further-
more, point mutations that lead to hyperstable or
unstable capsids, or to capsids with aberrant morpholo-
gies, lead almost systematically to reduced infectivity
[14], indicating that the shape and stability of the capsid
are also critical for HIV-1 infectivity.
The necessity of uncoating for HIV-1 and
other lentiviruses
HIV-1 and other lentiviruses are unique among orthore-
troviruses in their ability to replicate efficiently in meta-
bolically active non-dividing cells [15,16] as a result of
the active nuclear import of their genome across the
nuclear membrane of interphasic nuclei [17]. Retro-
viruses such as the Murine Leukaemia Virus (MLV)
gain access to the nuclear chromatin following the disas-
sembly of the nuclear membrane that occurs during
mitosis [18]. For such retroviruses, evidence suggests
that the viral capsid accompanies the viral genome into
the nuclear compartment and participates in interaction
with the chromatin [19] indicating that uncoating is not
required prior to nuclear import.
HIV and other lentiviruses enter the nuclei via the
nuclear pore; and, although commonly assumed, it is by
no means certain that they can use an alternative route
of entry during mitosis. Indeed, the replication of certain
lentiviruses (such as EIAV, CAEV and VISNA) is entirely
limited to macrophages, which do not divide. In the case
of HIV-1, which infects cycling CD4+ T cells in addition
to macrophages, a mitosis-independent nuclear import in
cycling cells has been reported [20]. Furthermore, a gen-
ome-wide RNA interference-based screen comparing
HIV-1 and MLV infections identified unique nuclear
import factors for HIV-1 even though the study was car-
ried out in cycling cells [21]. In addition, HIV-1 mutants
with a nuclear import defect in cell cycle-arrested cells
often maintain this defect in cycling cells [22-25]. Finally,
the assumption that HIV-1 might passively gain access to
the chromatin upon mitosis, if based on the belief that
cytoplasmic and nuclear contents mix homogeneously
throughout mitosis, is not valid. Indeed, evidence sug-
gests that mitotic cells maintain spatial information
through gradients, such as the RanGTP gradient that sur-
rounds chromatin [26,27]. Taken together, it is probable
that HIV-1 enters nuclei only through the nuclear pore
whether cells divide or not.
The dependency of lentiviruses on non-dividing cells
for in vivo transmission and persistence and the result-
ing necessity to enter the nucleus through the nuclear
pore impose an uncoating step because the diameter of
the viral capsid (up to 60 nm wide) exceeds that of the
nuclear pore (~30 nm). Consistent with this notion, pre-
vious work has reported a substantial difference in mass
between cytoplasmic and nuclear HIV-1 complexes
[28,29] and the absence of CA within pre-integration
complexes [30,31].
Where and when does uncoating occur?
Although most agree that uncoating occurs after fusion-
dependent entry in the cytoplasm and before nuclear
Figure 1 Scanning electron microscopy imaging of HIV-1
capsids in the cytoplasm and at the nuclear membrane of
infected cells. (A) Schematic representation of the mature HIV-1
capsid shell. The HIV-1 capsid is an assembly of approximately 1,500
CA monomers arranged into a hexagonal array of hexamers.
Dimensions are derived from microscopy observations of mature
virions or isolated cores. (B-D) Images show the backscattered gold
signal corresponding to specific labelling with a mouse monoclonal
anti-p24 antibody (183-H12-5C AIDS Reagent Program) followed
with goat anti-mouse IgG H&L conjugated 10 nm gold (British
Biocell International) in HIV-1 infected P4-CCR5 cells. HIV-1 capsids
are typically conical- or cylindrical-shaped, ca 100-150 nm long, and
heavily labelled with 10-30 immunogold particles. The bulk of
antibodies likely induces some distortions in size and shape of
capsids. In panels B and D, capsids are located at the nuclear
membrane: nuclear pore complexes appear as bright rings with
dark lumen.
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import, the field remains divided as to the precise
moment and location for this event. Indeed, the extent
of the role of HIV-1 capsid at early stages of infection is
still a matter of debate. In a first model, the viral capsid
is disassembled close to the plasma membrane immedi-
ately following fusion into the cytoplasm and most CA
is dissociated from the HIV-1 nucleoprotein complex
[32-35]. Uncoating is required for formation of the
reverse transcription complex (RTC) and is likely trig-
gered by the sudden change in environment in which
the viral complex finds itself, or possibly by the loss of
high concentrations of free CA present in virions and
responsible for maintaining metastable cores [36]. In
this model, the absence of significant amounts of CA
within intracellular HIV-1 complexes soon after inocula-
tion [28,29,37-39] and the inability to detect capsids in
the cytoplasm of infected cells using transmission elec-
tron microscopy (TEM) [40] led to the conclusion that
the primary function of HIV-1 capsid is to deliver the
viral genome into the cytoplasm, after which it can and
must be discarded for productive infection to proceed,
although it is not excluded that initial disassembly is
partial [32-35].
A second model proposes that capsid remains intact
for some time post-entry, at least for the initiation of
reverse transcription, and that uncoating occurs gradu-
ally during transport towards the nucleus and reverse
transcription [41]. In this model, uncoating is promoted
in response to multiple successive changes in the cellu-
lar environment, sequential contact with different cell
factors, and through the molecular rearrangements that
accompany reverse transcription, thus triggering pro-
gressive or stepwise conformational changes and disas-
sembly. In support of this hypothesis are studies that
report a broad range of different sizes and shapes for
cytoplasmic HIV-1, both greater and smaller than
mature extracellular cores, suggesting a complex series
of transformations accompanying reverse transcription
and transport to the nucleus [39,41-43] (although it can-
not be excluded that the observed variations are due to
the preparation or isolation protocol [44]), immuno-
fluorescent microscopy showing association of CA with
RTCs [42], and the demonstration that capsids with
increased or decreased core stability has impaired
reverse transcription [14].
A third model, which we favour, proposes that capsids
remain intact until HIV-1 incoming complexes reach
the nuclear membrane and that uncoating occurs at the
nuclear pore upon completion of reverse transcription.
In this model, the HIV-1 capsid is all-important for
maintaining a high stoichiometry of HIV-1 reverse tran-
scriptase enzyme relative to the viral genome during
reverse transcription to counteract its tendency to dis-
sociate from its template [45], since dilution of reverse
transcriptase in the cytoplasm would lead to highly inef-
fective reverse transcription. While it organises the
HIV-1 viral genome and proteins, it offers no imperme-
able environment from small macromolecules of the
cytoplasm: the capsid lattice is an open structure, with
inter-ring spacings of up to 10 nm [6], which allow
small macromolecules, such as nucleotide triphosphates
and indeed reverse transcriptase inhibitors, to access the
reverse transcription complex in the cytoplasm of
infected cells. While the first model proposes that
uncoating (at the plasma membrane) is required to trig-
ger viral reverse transcription, this third model suggests
that it is the successful completion of reverse transcrip-
tion (at the nuclear pore) that triggers uncoating.
Recent evidence suggests that the integrity and timely
disassembly of the HIV-1 capsid are essential for routing
to the nuclear compartment, reverse transcription and
successful nuclear import [14,29,46-48]. For this reason,
there is an increasing appeal to determine up to which
point the viral capsid is required for infection and at
which point in space and time it is disassembled.
Uncoating accompanies the conversion of RTCs
into pre-integration complexes (PICs)
In early replication, incoming HIV-1 is referred to either
as an RTC or as a PIC. The literature is divided as to
the nature and location in the cell of HIV-1 RTCs and
PICs, and most importantly as to the presence or lack
of capsid in these complexes. RTCs are simply defined
as HIV-1 complexes that undergo reverse transcription,
during which they convert their single-stranded positive
RNA viral genome into double-stranded DNA [49,50]
(Figure 2). The RTC genomes are thus either RNA or
RNA-DNA intermediates of reverse transcription. In
contrast, PICs no longer contain any RNA but only the
double-stranded DNA. PICs are per definition integra-
tion-competent HIV-1 complexes and can integrate effi-
ciently into a target DNA in vitro [51,52]. They are
formed in the cytoplasm upon synthesis of full-length
viral DNA and then translocate into the nucleus where
they form the integrated provirus.
It is assumed that reverse transcription is triggered by
the exposure of the viral complex to non-limiting deox-
yribonucleotides in the cytoplasm [44]. Reverse tran-
scription involves firstly the formation of the minus
strand strong-stop DNA, a strand transfer event, and
the synthesis of the minus strand DNA with concomi-
tant degradation of the RNA template. In the HIV-1
genome, two polypurine tracts (PPT), the central PPT
(cPPT) and 3’ PPT, resist degradation by RNase H and
serve as primers for synthesis of plus-strand DNA
[49,53,54]. Reverse transcription proceeds with synthesis
of plus-strand DNA, involves a second strand transfer
event, and terminates at a central termination sequence
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(CTS) in the centre of the genome. The initiation of
plus-strand synthesis at the cPPT, as well as the 3’ PPT
common to all retroviruses, leads to a discrete plus-
strand displacement of ca 100 nucleotides in the centre
of the genome (Figure 2). The final product of HIV-1
reverse transcription is therefore a linear double-
stranded DNA with a central DNA Flap [54]. The dura-
tion of reverse transcription varies according to the
metabolic state of the cell and in the case of asynchro-
nous infection. Full-length linear DNA may be detected
as early as 4 h post-infection but reaches its peak at
8-12 h post-infection [22,55,56]. Upon DNA Flap forma-
tion and completion of reverse transcription, the viral
complex becomes a PIC, competent for import into the
nucleus and integration within the host cell chromatin.
In the PIC, the ~ 9.7 kb HIV-1 genome, which would
per definition measure up to 3.3 μm, is compacted into
a 56 nm diameter object [31], possibly by viral and/or
cellular proteins that additionally could render it karyo-
philic for passage through the nuclear pore. Although
the complete identification of PIC components remains
elusive due to the difficulty to isolate PICs from infected
cells, many viral and cellular factors have been identified
as PIC components [34]. PICs are devoid of detectable
CA proteins [30,31] and contain IN [30]. The presence
of other viral proteins such as NC, matrix (MA), RT
and Vpr is a source of debate [28-31,37]. Several cellular
factors have also been shown to associate with HIV-1
PICs, such as the high mobility group protein HMG I
(Y) [31] and LEDGF/p75 [57]. Although interaction of
these cellular factors with HIV-1 PICs may occur in the
cytoplasm, their role in HIV-1 infection becomes appar-
ent in the nucleus where they may assist tethering of
the PIC to the chromatin, determine integration site
selection and assist integration [31,58,59].
Clearly, the transition between RTC and PIC is asso-
ciated with uncoating, however the fragile nature of the
HIV-1 capsid and the complexity of the early phases of
HIV-1 infection have made it particularly difficult to
pinpoint when this occurs.
Experimental hurdles to studying the fate of
HIV-1 capsids in newly infected cells
The most straightforward way to study uncoating in
infected cells is to isolate RTCs at given time points
post-infection using sedimentation velocity gradients
and to probe for co-sedimentation of CA with the viral
genome; or conversely to immunoprecipitate cellular
extracts with anti-CA antibodies and probe for viral
genome by PCR. Using these approaches, CA was not
found to be substantially associated with the viral gen-
ome within the cytoplasm of infected cells, thus lead-
ing to the conclusion that the viral capsid is discarded
from RTCs rapidly after cell entry [28,29,37-39]. How-
ever, the HIV-1 capsid is inherently unstable and
disassembles readily in the presence of non-ionic
detergents and upon ultracentrifugation [2,60]. More-
over the size, shape and components of isolated RTCs
are highly dependent on the conditions used for
isolation, particularly on the detergent and salt concen-
trations [44]. Therefore, it cannot be excluded that
the complexes analysed by biochemical isolation
Figure 2 Schematic representation of reverse transcription in
lentiviruses and other orthoretroviruses (such as MLV). The
conversion of the single-strand RNA genome (represented as a
black line) into double stranded DNA genome (at the bottom of
the diagram) is the hallmark of retroviruses. Reverse transcription is
initiated by the synthesis of minus-strand DNA (in green) at the PBS
site (Primer Binding Site) at the 5’ end of the RNA genome. The
minus-strand strong-stop DNA thus synthesised is then transferred
to the 3’ end of the genome through complementarity with the R
(Repeated) region of the LTR region (Long-Terminal Region) thus
allowing synthesis of the minus-strand DNA to be completed. Minus
strand DNA synthesis is accompanied by progressive degradation of
the RNA matrix by the RNase H activity of reverse transcriptase. Two
RNA sequences resist RNase degradation because they contain a
unique PPT sequence and these serve as initiation sites for the plus-
strand DNA. In all retroviruses, plus-strand DNA synthesis (in red) is
initiated at the 3’PPT. In the case of lentiviruses, initiation also takes
place at the cPPT. After a second strand transfer, plus-strand DNA
synthesis proceeds to generate double-stranded DNA. In the case of
lentiviruses, plus-strand initiation in two distinct sites leads to a
displacement of the downstream strand over ca 100 nucleotides,
terminating at the CTS and thus generating a discrete strand
displacement called the central DNA Flap.
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approaches have in fact lost their capsid during the
isolation procedure.
A further difficulty comes from the fact that most
incoming viral complexes are more likely to be destined
for degradation than on a productive pathway for infec-
tion since over 85% of viruses that have entered the cell
do not form proviruses [61]. This is the case of viral
particles that have entered by endocytosis [62] and of
functional RTCs that are lost in the routing process
towards the nucleus [42]. As a result, the majority of
cytoplasmic RTCs isolated early after infection likely
represent complexes that were damaged or engaged in a
pathway of degradation at the time of isolation or
observation.
In order to circumvent the need to isolate RTCs from
infected cells, some groups have attempted to visualise
HIV-1 capsids by in situ ultrastructural electron micro-
scopy in infected cells. Generally speaking however, it is
difficult to follow the fate of viral complexes inside the
cytoplasm using morphological criteria in sections of
electron microscopy (EM) [63]. Indeed, a single viral
capsid would be almost impossible to distinguish from
other cytoplasmic components unless it was fortuitously
cut right along the length of the capsid, thus displaying
its unusual conical morphology. Any other cut will lead
to heterogeneous circular and ovoid structures. Further-
more, the visualisation of intracellular capsids within a
60 nm thick EM slice, which represents less than 1:50th
of the cell thickness, is per definition a rare event. Using
this ultrastructural approach with TEM, few [47] or no
[40] intact virus cores were observed in the cytoplasm
of infected cells.
The intrinsic difficulty of studying HIV-1 uncoating has
driven the development of alternative approaches. Using
in situ immunohistochemical approaches, HIV-1 CA is
readily detected throughout the cytoplasm of infected
cells and co-localises with the viral genome [42,47].
Nevertheless, in order to demonstrate that this CA signal
corresponds to capsid cores rather than soluble CA,
immunolabelling of CA or detection of the viral genome
must be combined with ultrastructural observations. This
is especially difficult to achieve using TEM since prepara-
tions generally favour either ultrastructural observations
or immunolabelling. One approach to overcome this
involves detection of the viral DNA using in situ hybridi-
sation with electron microscopy [64] without the usual
protease treatment in order to preserve proteinaceous
structures as much as possible. Using this approach, cap-
sid shells could be detected around the viral genome but
with weak intensity [47]. An alternative approach
involves observing intracellular complexes, in situ via a
scanning EM (SEM), in cells stripped of their plasma
membrane [47,65]. This ultrastructural approach may be
readily combined with immunolabelling and may enable
the observation of intracellular HIV-1 capsids, identified
by specific anti-CA labelling and a morphology similar to
intact viral cores [47] (Figure 1).
To study uncoating in a quantitative manner, particu-
late (intact) capsids may be separated from soluble
(monomeric) CA by ultracentrifugation of virions
through a sucrose cushion overlaid with a low concen-
tration of detergent [66]. This cell-free assay enabled to
analyse the effects of mutations on capsid stability
[14,67,68] and of reverse transcription on capsid integ-
rity [47]. A variation of this assay enables the study of
capsid uncoating in infected cells by carefully designed
ultracentrifugation of cell lysates through a sucrose
cushion, which separates cytosolic cores from soluble
CA [69]. This fate-of-capsid assay has been used for
example to establish a correlation between retroviral
restriction and accelerated uncoating [69,70], to study
capsid stability in infected cells [71], and quantify retro-
viral restriction potency and kinetics [72,73].
Given the complexity and fragile nature of the HIV-1
capsids, there is still a need for sensitive, specific and
reliable assays for uncoating. No assay may be relied
upon solely when interpreting uncoating events.
Timely uncoating is key for HIV-1 reverse
transcription, nuclear import and infectivity
Lessons from retroviral restriction: premature uncoating
leads to abortive infection
The tripartite motif 5-alpha (TRIM5a) protein is a
dominant factor of intrinsic immunity that mediates cel-
lular restriction against retroviral infections in a species-
specific manner [74,75] and was originally discovered
as a determinant of the resistance of monkey cells to
HIV-1 infection [76]. Although the exact mechanisms
that lead to virus inactivation by TRIM5a proteins
remain unclear [77], it is known that TRIM5a targets
intact retroviral capsids early in viral replication prior to
reverse transcription, by interacting directly with these
through its B30.2 (SPRY) C-terminal domain [69,78,79].
Interestingly, Fv1 restriction of MLV in mouse cells,
although known to involve different mechanisms than
TRIM5a, also targets capsid cores [80,81]. Retroviral
restriction mechanisms are thought to have evolved in
many species including primates as a result of evolution-
ary pressure exerted by continual exposure to retro-
viruses [77]. The startling evolutionary conservation of
recognition of capsid cores as restriction mechanism
suggests that their structure, composition and stability
are key to retroviral infections.
In the case of restriction of HIV-1 in rhesus macaque
cells, it was originally supposed that TRIM5a binding
might inhibit the uncoating of the viral capsid [82,83],
thought to be required for reverse transcription to initi-
ate in the cytoplasm of newly infected cells. However,
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more recent work indicates that TRIM5a, quite on the
contrary, promotes the rapid and premature disassembly
of viral capsids thus abrogating productive reverse tran-
scription [69,70,84] (Figure 3). These findings indicated
for the first time that premature uncoating of HIV-1, far
from being beneficial for initiation of reverse transcrip-
tion and infection, is in fact detrimental to both and is
the molecular cornerstone for potent species-specific
retroviral restrictions. This suggests that the stability
and integrity of HIV-1 capsids during the early steps of
infection is key to effective replication. In support of
this are findings that capsid mutants with either reduced
or increased stability compromise almost systematically
HIV-1 infection [14] (Figure 3), indicating that both too
rapid and too slow uncoating are detrimental for HIV-1
infection.
Lessons from reverse transcription: unsuccessful reverse
transcription precludes uncoating
One hypothesis proposes that uncoating might occur in
response to changes in viral nucleic acid nature and
structure, rather than in changes in cellular environ-
ment. If this were the case, then inhibiting reverse tran-
scription would be expected to arrest uncoating at a
very defined and reproducible step. Strikingly, blocking
reverse transcription by a reverse transcriptase inhibitor
(Nevirapine) resulted in the accumulation of conical
capsid cores in proximity to and at the nuclear mem-
brane and nuclear pores at late time points post-
infection [47]. These were formally identified as HIV-1
capsids based on specific anti-CA labelling and morpho-
logical criteria, and were shown to contain the viral gen-
ome using EM in situ hybridisation. An accumulation of
intact capsids at the nuclear membrane was also
observed in the case of inhibition of DNA Flap forma-
tion, the last chronological event of reverse transcription
[47] (Figure 1). Therefore, although incoming HIV-1
capsids may undergo stepwise destabilisation during cell
entry and cytoplasmic transport, these data suggest that
HIV-1 uncoating is not progressive but occurs upon
completion of reverse transcription. They also suggest
that progression through reverse transcription and
uncoating is independent of transport towards the
nucleus.
Lessons from nuclear import: timely uncoating underlies
the ability of HIV-1 to infect non-dividing cells
The search for the determinants of nuclear import
that allow HIV-1 and other lentiviruses to infect non-
dividing cells is an active and controversial field of
investigation [85]. Based on the search of nuclear locali-
zation sequences, a number of HIV-1 proteins have
been proposed to contribute in a redundant manner to
the karyophilic properties of the HIV-1 PIC but the
actual participation of these proteins in HIV-1 genome
nuclear import has been a matter of strong debate [85].
The integrase protein, which is tightly associated with
PICs until the integration of the viral DNA into the host
chromosomes, is karyophilic and may participate in
HIV-1 nuclear import. The cis-acting sequences cPPT
and CTS, which form the central DNA Flap during
reverse transcription, have also been identified as deter-
minants of HIV-1 genome nuclear import [22] and are
as a result systematically inserted within lentiviral vec-
tors to enhance gene transfer efficiencies.
Intriguingly, recent work based on capsid mutants or
chimeras has introduced the existence of a functional
link between the HIV-1 CA and nuclear import
[46,48,86], underlying the importance of timely uncoat-
ing for nuclear import. Furthermore, the requirement of
HIV-1 nuclear import for transportin-SR2 [87] [88], also
called TNPO3, has been mapped to the HIV-1 CA [89].
Although an interaction between HIV-1 capsid and
TNPO3 remains to be demonstrated, a CA point muta-
tion renders HIV-1 insensitive to TNPO3 knockdown
[90]. Uncoating is necessary for passage through the
nuclear pore, and HIV-1 complexes that fail to uncoat
will accumulate at the cytoplasmic face of the nuclear
membrane [47]. However, these data further suggest
that HIV-1 CA may also be essential to mediate interac-
tion with the nuclear pore, with transport proteins such
as transportin-SR2, or with nucleoporins prior to
uncoating.
Figure 3 Schematic representation of the fates of viral capsids
in the cytoplasm of newly infected cells. After entry into the
cytoplasm, HIV-1 capsids that are on a path of productive infection
remain intact and are transported towards the nucleus along the
cytoskeleton. They uncoat at the nuclear membrane upon
completion of reverse transcription. Premature uncoating, in the
case of TRIM5a restriction or of unstable capsid mutants, leads to
abortive infection. Similarly, compromised uncoating, in the case of
incomplete reverse transcription or of hyperstable capsid mutants,
also leads to a dead-end infection event.
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Conclusion: rethinking HIV-1 uncoating
Previous work led us to suppose that the HIV-1 capsid
core, although all-essential for initial delivery into the
cytoplasm, is then discarded immediately post-fusion to
stimulate reverse transcription. Others propose that
uncoating probably occurs gradually, possibly in
response to multiple cellular cues such as interaction
with cellular proteins or subcellular localisation, or viral
cues such as the progress of reverse transcription.
Although incoming capsids may undergo progressive
destabilisation during their transport towards the
nucleus, since hyperstable capsid mutants have impaired
reverse transcription [14], recent independent experi-
ments suggest that the position and timing of uncoating
may in fact be tightly regulated and have a trigger.
Uncoating must be neither too early nor too late in
order to ensure productive infection (Figure 3).
Although the intricacies of HIV-1 uncoating - its tim-
ing, location and mechanism - are by no means
resolved, recent work enables us to etch a possible
model for the early steps of HIV-1 infection. Entry of
HIV-1 into target cells delivers the intact capsid core
into the cytoplasm and exposure of the viral nucleopro-
tein complex to non-limiting deoxyribonucleotides trig-
gers reverse transcription. This likely occurs within the
intact capsid core, which is essential for maintaining a
high concentration of enzyme around the nucleic acid
while being entirely permeable to the necessary deoxyri-
bonucleotides. During reverse transcription, HIV-1
RTCs move rapidly toward the nuclear compartment,
using microtubules then actin filaments to reach the
nuclear pore [42,47]. Since transport to the nuclear pore
(within minutes to 1-2 hours) is more rapid than reverse
transcription (8-12 hours), it is likely that most viral
DNA synthesis occurs within capsid cores docked at the
nuclear pore. This implies that subcellular fractionation
experiments that do not distinguish between nuclear
membrane and nucleoplasm are in fact incapable of dis-
tinguishing nuclear from cytoplasmic HIV-1 complexes.
Indeed, HIV-1 complexes docked at the nuclear mem-
brane will appear in the nuclear fraction even though
they are in fact in the cytoplasm. The presence of intact
HIV-1 capsids at the nuclear membrane further implies
that the most likely viral structure that interacts with
the host cell during transport towards the nucleus is the
capsid core. Using a yeast-two-hybrid screen and inter-
action assays with capsid cores, we identified several
components of the microtubule and actin network as
interaction partners for HIV-1 capsid and essential co-
factors of HIV-1 infection (A. Becker, S. Munier, N.
Arhel, unpublished data). Therefore, as well as being
essential for reverse transcription, the capsid shell may
also be key to bringing viral complexes to their site of
replication.
One hypothesis brought forward is that the comple-
tion of reverse transcription and the formation of the
central DNA Flap trigger or facilitate uncoating [47]. If
this is the case, then the trigger for uncoating is not a
cellular cue, as is the case for adenoviruses [91] or
herpes simplex virus type 1 [92], but a viral signal. Con-
cordant with this, uncoating can occur in vitro upon
synthesis of full-length viral DNA by endogenous
reverse transcription, suggesting that any cellular factors
required for uncoating are present within HIV-1 virions
[47]. Apart from the DNA Flap, other viral and cellular
factors have been proposed to participate in uncoating,
including IN [93], prolyl isomerases Pin1 [94] and
Cyclophilin A [72], and cellular factors present in non-
resting cells [95].
A further hypothesis is that uncoating occurs at the
nuclear pore [47] and allows PICs to be imported into
the nucleus. Consistent with this is the fact that CA
may constitute a determinant of HIV-1 PIC nuclear
import [46,48,86,89]. Premature uncoating, as in the
case of TRIM5a restriction or unstable capsid mutants,
leads to abortive infection. Similarly, complexes that fail
to uncoat, such as hyperstable capsid mutants or in the
case of inhibited reverse transcription, cannot be
imported into the nucleus.
Much of previous work was interpreted in light of the
assumption that HIV-1 uncoating occurred immediately
post-fusion and the association of CA with intracellular
HIV-1 was understood to be detrimental for HIV-1
infection. If we accept the premise that HIV-1 capsids
uncoat at the nuclear pore upon completion of reverse
transcription, our interpretation of data must be
reversed: the loss of capsid cores after entry then corre-
sponds to early degradation products of abortive com-
plexes and the maintaining of intact capsids to
complexes on the path of productive infection.
Perspectives
The molecular mechanisms underlying the destabilisa-
tion and uncoating of HIV-1 in the cytoplasm of
infected cells remain to be elucidated. Both cytoplasmic
environment and major rearrangements of the RTC at
the end of reverse transcription could contribute to the
disassembly of capsids prior to nuclear import. Further-
more, the importance of timely uncoating for HIV-1
infection and the fact that the capsid is the target of
evolutionary conserved anti-retroviral restriction
mechanisms emphasise the interest to develop a new
class of anti-retroviral drugs that either accelerate or
entirely inhibit uncoating.
Arhel Retrovirology 2010, 7:96
http://www.retrovirology.com/content/7/1/96
Page 7 of 10
Acknowledgements
The author thanks the CNRS (Centre National de Recherche Scientifique), the
ANRS (Agence Nationale de Recherche sur le SIDA), the FRM (Fondation
pour la Recherche Médicale) and the Pasteur Institute for financial support,
Pierre Charneau and the members of his lab for helpful discussions, and
Sylvie Souquere-Besse for her expertise in electron microscopy. Apologies
are extended to those colleagues whose studies could not be mentioned
due to space limitation.
Competing interests
The author declares that they have no competing interests.
Received: 7 September 2010 Accepted: 17 November 2010
Published: 17 November 2010
References
1. Höglund S, Ofverstedt LG, Nilsson A, Lundquist P, Gelderblom H, Ozel M,
Skoglund U: Spatial visualization of the maturing HIV-1 core and its
linkage to the envelope. AIDS Res Hum Retroviruses 1992, 8:1-7.
2. Welker R, Hohenberg H, Tessmer U, Huckhagel C, Kräusslich HG:
Biochemical and structural analysis of isolated mature cores of human
immunodeficiency virus type 1. J Virol 2000, 74:1168-1177.
3. Briggs JA, Wilk T, Welker R, Kräusslich HG, Fuller SD: Structural organization
of authentic, mature HIV-1 virions and cores. EMBO J 2003, 22:1707-1715.
4. Benjamin J, Ganser-Pornillos BK, Tivol WF, Sundquist WI, Jensen GJ: Three-
dimensional structure of HIV-1 virus-like particles by electron
cryotomography. J Mol Biol 2005, 346:577-588.
5. Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI: Assembly and analysis
of conical models for the HIV-1 core. Science 1999, 283:80-83.
6. Li S, Hill CP, Sundquist WI, Finch JT: Image reconstructions of helical
assemblies of the HIV-1 CA protein. Nature 2000, 407:409-413.
7. Ganser-Pornillos BK, Cheng A, Yeager M: Structure of full-length HIV-1 CA:
a model for the mature capsid lattice. Cell 2007, 131:70-79.
8. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD,
Sundquist WI, Hill CP, Yeager M: X-ray structures of the hexameric
building block of the HIV capsid. Cell 2009, 137:1282-1292.
9. Vogt VM: Retroviral virions and genomes.Edited by: Coffin JM, Hughes SH,
Varmus HE. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press;
1997:27-69.
10. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG:
Sequential steps in human immunodeficiency virus particle maturation
revealed by alterations of individual Gag polyprotein cleavage sites.
J Virol 1998, 72:2846-2854.
11. Krausslich HG, Facke M, Heuser AM, Konvalinka J, Zentgraf H: The spacer
peptide between human immunodeficiency virus capsid and
nucleocapsid proteins is essential for ordered assembly and viral
infectivity. J Virol 1995, 69:3407-3419.
12. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C,
Castillo A, Zoumplis D, Orenstein JM, Allaway GP, Freed EO, Wild CT:
PA-457: a potent HIV inhibitor that disrupts core condensation by
targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003,
100:13555-13560.
13. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken C,
Chen CH: Small-molecule inhibition of human immunodeficiency virus
type 1 replication by specific targeting of the final step of virion
maturation. J Virol 2004, 78:922-929.
14. Forshey BM, von Schwedler U, Sundquist WI, Aiken C: Formation of a
human immunodeficiency virus type 1 core of optimal stability is crucial
for viral replication. J Virol 2002, 76:5667-5677.
15. Gartner S, Markovits P, Markovitz DM, Betts RF, Popovic M: Virus isolation
from and identification of HTLV-III/LAV-producing cells in brain tissue
from a patient with AIDS. JAMA 1986, 256:2365-2371.
16. Weinberg JB, Matthews TJ, Cullen BR, Malim MH: Productive human
immunodeficiency virus type 1 (HIV-1) infection of nonproliferating
human monocytes. J Exp Med 1991, 174:1477-1482.
17. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG,
Haggerty S, Stevenson M: Active nuclear import of human
immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad
Sci USA 1992, 89:6580-6584.
18. Roe T, Reynolds TC, Yu G, Brown PO: Integration of murine leukemia virus
DNA depends on mitosis. EMBO J 1993, 12:2099-2108.
19. Bowerman B, Brown PO, Bishop JM, Varmus HE: A nucleoprotein complex
mediates the integration of retroviral DNA. Genes Dev 1989, 3:469-478.
20. Katz RA, Greger JG, Boimel P, Skalka AM: Human immunodeficiency virus
type 1 DNA nuclear import and integration are mitosis independent in
cycling cells. J Virol 2003, 77:13412-13417.
21. König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY,
Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS,
Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ,
Bushman FD, Young JA, Chanda SK: Global analysis of host-pathogen
interactions that regulate early-stage HIV-1 replication. Cell 2008,
135:49-60.
22. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P: HIV-1
genome nuclear import is mediated by a central DNA flap. Cell 2000,
101:173-85.
23. Bouyac-Bertoia M, Dvorin JD, Fouchier RA, Jenkins Y, Meyer BE, Wu LI,
Emerman M, Malim MH: HIV-1 infection requires a functional integrase
NLS. Mol Cell 2001, 7:1025-1035.
24. Ao Z, Yao X, Cohen EA: Assessment of the role of the central DNA flap in
human immunodeficiency virus type 1 replication by using a single-
cycle replication system. J Virol 2004, 78:3170-3177.
25. Arhel N, Munier S, Souque P, Mollier K, Charneau P: Nuclear import defect
of human immunodeficiency virus type 1 DNA flap mutants is not
dependent on the viral strain or target cell type. J Virol 2006,
80:10262-10269.
26. Fuller BG: Self-organization of intracellular gradients during mitosis. Cell
Div 2010, 5:5.
27. Kalab P, Heald R: The RanGTP gradient - a GPS for the mitotic spindle.
J Cell Sci 2008, 121:1577-1586.
28. Karageorgos L, Li P, Burrell C: Characterization of HIV replication
complexes early after cell-to-cell infection. AIDS Res Hum Retroviruses
1993, 9:817-823.
29. Iordanskiy S, Berro R, Altieri M, Kashanchi F, Bukrinsky M: Intracytoplasmic
maturation of the human immunodeficiency virus type 1 reverse
transcription complexes determines their capacity to integrate into
chromatin. Retrovirology 2006, 3:4.
30. Farnet CM, Haseltine WA: Determination of viral proteins present in the
human immunodeficiency virus type 1 preintegration complex. J Virol
1991, 65:1910-1915.
31. Miller MD, Farnet CM, Bushman FD: Human immunodeficiency virus type
1 preintegration complexes: studies of organization and composition.
J Virol 1997, 71:5382-5390.
32. Bukrinsky M: A hard way to the nucleus. Mol Med 2004, 10:1-5.
33. Lehmann-Che J, Saïb A: Early stages of HIV replication: how to hijack
cellular functions for a successful infection. AIDS Rev 2004, 6:199-207.
34. Suzuki Y, Craigie R: The road to chromatin - nuclear entry of retroviruses.
Nat Rev Microbiol 2007, 5:187-196.
35. Dvorin JD, Malim MH: Intracellular trafficking of HIV-1 cores: journey to
the center of the cell. Curr Top Microbiol Immunol 2003, 281:179-208.
36. Mortuza GB, Haire LF, Stevens A, Smerdon SJ, Stoye JP, Taylor I: High-
resolution structure of a retroviral capsid hexameric amino-terminal
domain. Nature 2004, 431:481-485.
37. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG,
Stevenson M: Association of integrase, matrix, and reverse transcriptase
antigens of human immunodeficiency virus type 1 with viral nucleic
acids following acute infection. Proc Natl Acad Sci USA 1993, 90:6125-6129.
38. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V,
Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M: The Vpr
protein of human immunodeficiency virus type 1 influences nuclear
localization of viral nucleic acids in nondividing host cells. Proc Natl Acad
Sci USA 1994, 91:7311-7315.
39. Fassati A, Goff SP: Characterization of intracellular reverse transcription
complexes of human immunodeficiency virus type 1. J Virol 2001,
75:3626-3635.
40. Grewe C, Beck A, Gelderblom HR: HIV: early virus-cell interactions. J Acquir
Immune Defic Syndr 1990, 3:965-974.
41. Warrilow D, Tachedjian G, Harrich D: Maturation of the HIV reverse
transcription complex: putting the jigsaw together. Rev Med Virol 2009,
19:324-337.
42. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M,
Hope TJ: Visualization of the intracellular behavior of HIV in living cells.
J Cell Biol 2002, 159:441-452.
Arhel Retrovirology 2010, 7:96
http://www.retrovirology.com/content/7/1/96
Page 8 of 10
43. Nermut MV, Fassati A: Structural analyses of purified human
immunodeficiency virus type 1 intracellular reverse transcription
complexes. J Virol 2003, 77:8196-8206.
44. Goff SP: Intracellular trafficking of retroviral genomes during the early
phase of infection: viral exploitation of cellular pathways. J Gene Med
2001, 3:517-528.
45. Klarmann GJ, Schauber CA, Preston BD: Template-directed pausing of
DNA synthesis by HIV-1 reverse transcriptase during polymerization of
HIV-1 sequences in vitro. J Biol Chem 1993, 268:9793-9802.
46. Dismuke DJ, Aiken C: Evidence for a functional link between uncoating
of the human immunodeficiency virus type 1 core and nuclear import
of the viral preintegration complex. J Virol 2006, 80:3712-3720.
47. Arhel NJ, Souquere-Besse S, Munier S, Souque P, Guadagnini S,
Rutherford S, Prévost MC, Allen TD, Charneau P: HIV-1 DNA Flap formation
promotes uncoating of the pre-integration complex at the nuclear pore.
EMBO J 2007, 26:3025-3037.
48. Yamashita M, Perez O, Hope TJ, Emerman M: Evidence for direct
involvement of the capsid protein in HIV infection of nondividing cells.
PLoS Pathog 2007, 3:1502-1510.
49. Telesnitsky A, Goff SP: Reverse transcriptase and the generation of
retroviral DNA. In Retroviruses. Edited by: Coffin JM, Hughes SH, Varmus HE.
Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press; 1997:121-160.
50. Basu VP, Song M, Gao L, Rigby ST, Hanson MN, Bambara RA: Strand
transfer events during HIV-1 reverse transcription. Virus Res 2008,
134:19-38.
51. Ellison V, Abrams H, Roe T, Lifson J, Brown P: Human immunodeficiency
virus integration in a cell-free system. J Virol 1990, 64:2711-2715.
52. Farnet CM, Haseltine WA: Integration of human immunodeficiency virus
type 1 DNA in vitro. Proc Natl Acad Sci USA 1990, , 87: 4164-4168.
53. Charneau P, Alizon M, Clavel F: A second origin of DNA plus-strand
synthesis is required for optimal human immunodeficiency virus
replication. J Virol 1992, 66:2814-2820.
54. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F: HIV-1 reverse
transcription. A termination step at the center of the genome. J Mol Biol
1994, 241:651-662.
55. Kim SY, Byrn R, Groopman J, Baltimore D: Temporal aspects of DNA and
RNA synthesis during human immunodeficiency virus infection:
evidence for differential gene expression. J Virol 1989, 63:3708-3713.
56. Barbosa P, Charneau P, Dumey N, Clavel F: Kinetic analysis of HIV-1 early
replicative steps in a coculture system. AIDS Res Hum Retroviruses 1994,
10:53-59.
57. Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M,
Poeschla EM: LEDGF/p75 determines cellular trafficking of diverse
lentiviral but not murine oncoretroviral integrase proteins and is a
component of functional lentiviral preintegration complexes. J Virol
2004, 78:9524-9537.
58. Emiliani S, Mousnier A, Busschots K, Maroun M, Van Maele B, Tempé D,
Vandekerckhove L, Moisant F, Ben-Slama L, Witvrouw M, Christ F, Rain JC,
Dargemont C, Debyser Z, Benarous R: Integrase mutants defective for
interaction with LEDGF/p75 are impaired in chromosome tethering and
HIV-1 replication. J Biol Chem 2005, 280:25517-25523.
59. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, Ecker JR,
Bushman F: A role for LEDGF/p75 in targeting HIV DNA integration. Nat
Med 2005, 11:1287-1289.
60. Borroto-Esoda K, Boone LR: Equine infectious anemia virus and human
immunodeficiency virus DNA synthesis in vitro: characterization of the
endogenous reverse transcriptase reaction. J Virol 1991, 65:1952-1959.
61. Thomas JA, Ott DE, Gorelick RJ: Efficiency of human immunodeficiency
virus type 1 postentry infection processes: evidence against
disproportionate numbers of defective virions. J Virol 2007, 81:4367-4370.
62. Maréchal V, Clavel F, Heard JM, Schwartz O: Cytosolic Gag p24 as an index
of productive entry of human immunodeficiency virus type 1. J Virol
1998, 72:2208-2212.
63. Risco C, Menéndez-Arias L, Copeland TD, Pinto da Silva P, Oroszlan S:
Intracellular transport of the murine leukemia virus during acute
infection of NIH 3T3 cells: nuclear import of nucleocapsid protein and
integrase. J Cell Sci 1995, 108:3039-3050.
64. Arhel NJ, Souquere-Besse S, Charneau P: Wild-type and central DNA flap
defective HIV-1 lentiviral vector genomes: intracellular visualization at
ultrastructural resolution levels. Retrovirology 2006, 3:38.
65. Allen TD, Rutherford SA, Murray S, Gardiner F, Kiseleva E, Goldberg MW,
Drummond SP: Visualization of the nucleus and nuclear envelope in situ
by SEM in tissue culture cells. Nat Protoc 2007, 2:1180-1184.
66. Aiken C: Cell-free assays for HIV-1 uncoating. Methods Mol Biol 2009,
485:41-53.
67. Wacharapornin P, Lauhakirti D, Auewarakul P: The effect of capsid
mutations on HIV-1 uncoating. Virology 2007, 358:48-54.
68. Brun S, Solignat M, Gay B, Bernard E, Chaloin L, Fenard D, Devaux C,
Chazal N, Briant L: VSV-G pseudotyping rescues HIV-1 CA mutations that
impair core assembly or stability. Retrovirology 2008, 5:57.
69. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F,
Anderson DJ, Sundquist WI, Sodroski J: Specific recognition and
accelerated uncoating of retroviral capsids by the TRIM5alpha restriction
factor. Proc Natl Acad Sci USA 2006, 103:5514-5519.
70. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, Sodroski J: The
human TRIM5alpha restriction factor mediates accelerated uncoating of
the N-tropic murine leukemia virus capsid. J Virol 2007, 81:2138-2148.
71. Li Y, Kar AK, Sodroski J: Target cell type-dependent modulation of human
immunodeficiency virus type 1 capsid disassembly by cyclophilin A.
J Virol 2009, 83:10951-10962.
72. Javanbakht H, Diaz-Griffero F, Yuan W, Yeung DF, Li X, Song B, Sodroski J:
The ability of multimerized cyclophilin A to restrict retrovirus infection.
Virology 2007, 367:19-29.
73. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J:
Comparative requirements for the restriction of retrovirus infection by
TRIM5alpha and TRIMCyp. Virology 2007, 369:400-410.
74. Nisole S, Stoye JP, Saïb A: TRIM family proteins: retroviral restriction and
antiviral defence. Nat Rev Microbiol 2005, 3:799-808.
75. Towers GJ: The control of viral infection by tripartite motif proteins and
cyclophilin A. Retrovirology 2007, 4:40.
76. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old
World monkeys. Nature 2004, 427:848-853.
77. Neil S, Bieniasz P: Human immunodeficiency virus, restriction factors, and
interferon. J Interferon Cytokine Res 2009, 29:569-580.
78. Sebastian S, Luban J: TRIM5alpha selectively binds a restriction-sensitive
retroviral capsid. Retrovirology 2005, 2:40.
79. Forshey BM, Shi J, Aiken C: Structural requirements for recognition of the
human immunodeficiency virus type 1 core during host restriction in
owl monkey cells. J Virol 2005, 79:869-875.
80. Goff SP: Retrovirus restriction factors. Mol Cell 2004, 16:849-859.
81. Bieniasz PD: Intrinsic immunity: a front-line defense against viral attack.
Nat Immunol 2004, 5:1109-1115.
82. Stevenson M: TRIMming HIV-1’s mainsail. Nat Immunol 2004, 5:355-356.
83. Goff SP: HIV: replication trimmed back. Nature 2004, 427:791-793.
84. Black LR, Aiken C: TRIM5alpha disrupts the structure of assembled HIV-1
capsid complexes in vitro. J Virol 2010, 84:6564-6569.
85. Fassati A: HIV infection of non-dividing cells: a divisive problem.
Retrovirology 2006, 3:74.
86. Yamashita M, Emerman M: Capsid is a dominant determinant of
retrovirus infectivity in nondividing cells. J Virol 2004, 78:5670-5678.
87. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ,
Lieberman J, Elledge SJ: Identification of host proteins required for HIV
infection through a functional genomic screen. Science 2008,
319(5865):921-6.
88. Christ F, Thys W, De Rijck J, Gijsbers R, Albanese A, Arosio D, Emiliani S,
Rain JC, Benarous R, Cereseto A, Debyser Z: Transportin-SR2 imports HIV
into the nucleus. Curr Biol 2008, 18:1192-1202.
89. Krishnan L, Matreyek KA, Oztop I, Lee K, Tipper CH, Li X, Dar MJ,
Kewalramani VN, Engelman A: The requirement for cellular transportin 3
(TNPO3 or TRN-SR2) during infection maps to human immunodeficiency
virus type 1 capsid and not integrase. J Virol 2010, 84:397-406.
90. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, Vandegraaff N,
Baumann JG, Wang R, Yuen W, Takemura T, Shelton K, Taniuchi I, Li Y,
Sodroski J, Littman DR, Coffin JM, Hughes SH, Unutmaz D, Engelman A,
KewalRamani VN: Flexible use of nuclear import pathways by HIV-1. Cell
Host Microbe 2010, 7:221-233.
91. Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF: Import of
adenovirus DNA involves the nuclear pore complex receptor CAN/
Nup214 and histone H1. Nat Cell Biol 2001, 3:1092-1100.
Arhel Retrovirology 2010, 7:96
http://www.retrovirology.com/content/7/1/96
Page 9 of 10
92. Ojala PM, Sodeik B, Ebersold MW, Kutay U, Helenius A: Herpes simplex
virus type 1 entry into host cells: reconstitution of capsid binding and
uncoating at the nuclear pore complex in vitro. Mol Cell Biol 2000,
20:4922-4931.
93. Briones MS, Dobard CW, Chow SA: Role of human immunodeficiency
virus type 1 integrase in uncoating of the viral core. J Virol 2010,
84:5181-5190.
94. Misumi S, Inoue M, Dochi T, Kishimoto N, Hasegawa N, Takamune N,
Shoji S: Uncoating of human immunodeficiency virus type 1 requires
prolyl isomerase Pin1. J Biol Chem 2010, 285:25185-25195.
95. Auewarakul P, Wacharapornin P, Srichatrapimuk S, Chutipongtanate S,
Puthavathana P: Uncoating of HIV-1 requires cellular activation. Virology
2005, 337:93-101.
doi:10.1186/1742-4690-7-96
Cite this article as: Arhel: Revisiting HIV-1 uncoating. Retrovirology 2010
7:96.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Arhel Retrovirology 2010, 7:96
http://www.retrovirology.com/content/7/1/96
Page 10 of 10
